These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24243516)

  • 1. A model-based economic evaluation of improved primary care management of patients with type 2 diabetes in Australia.
    Haji Ali Afzali H; Gray J; Beilby J; Holton C; Karnon J
    Appl Health Econ Health Policy; 2013 Dec; 11(6):661-70. PubMed ID: 24243516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A risk adjusted cost-effectiveness analysis of alternative models of nurse involvement in obesity management in primary care.
    Karnon J; Ali Afzali HH; Gray J; Holton C; Banham D; Beilby J
    Obesity (Silver Spring); 2013 Mar; 21(3):472-9. PubMed ID: 23592655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
    Tunis SL
    Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using an economic model of diabetes to evaluate prevention and care strategies in Australia.
    Colagiuri S; Walker AE
    Health Aff (Millwood); 2008; 27(1):256-68. PubMed ID: 18180502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
    Fonseca T; Clegg J; Caputo G; Norrbacka K; Dilla T; Alvarez M
    J Med Econ; 2013 Jul; 16(7):926-38. PubMed ID: 23659201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US.
    Tunis SL; Minshall ME
    Curr Med Res Opin; 2010 Jan; 26(1):151-62. PubMed ID: 19919376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of a quality improvement collaborative focusing on patients with diabetes.
    Schouten LM; Niessen LW; van de Pas JW; Grol RP; Hulscher ME
    Med Care; 2010 Oct; 48(10):884-91. PubMed ID: 20808258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ; Tucker DM
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Report on financing the new model of family medicine.
    Spann SJ;
    Ann Fam Med; 2004 Dec; 2 Suppl 3(Suppl 3):S1-21. PubMed ID: 15654084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
    Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of government subsidized pharmaceutical use in patients with diabetes or cardiovascular disease in a primary care setting: evidence from a prospective randomized trial.
    Hirst NG; Whitty JA; Synnott RL; Eley DS; Scuffham PA
    J Med Econ; 2011; 14(6):698-704. PubMed ID: 21892854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L; Zhao FL; Li SC
    Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL; Willis WD; Foos V
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings.
    de Salas-Cansado M; Pérez C; Saldaña MT; Navarro A; González-Gómez FJ; Ruiz L; Rejas J
    Prim Care Diabetes; 2012 Dec; 6(4):303-12. PubMed ID: 22595032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health economics analysis of insulin aspart vs. regular human insulin in type 2 diabetes patients, based on observational real life evidence from general practices in Germany.
    Liebl A; Seitz L; Palmer AJ
    Exp Clin Endocrinol Diabetes; 2014 Oct; 122(9):517-22. PubMed ID: 25148263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying organisational principles and management practices important to the quality of health care services for chronic conditions.
    Frølich A
    Dan Med J; 2012 Feb; 59(2):B4387. PubMed ID: 22293057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triggering factors of primary care costs in the years following type 2 diabetes diagnosis in Mexico.
    Castro-Ríos A; Nevárez-Sida A; Tiro-Sánchez MT; Wacher-Rodarte N
    Arch Med Res; 2014 Jul; 45(5):400-8. PubMed ID: 24825741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.